Articles
-
1 week ago |
fiercebiotech.com | James Waldron
The asset, dubbed KRRO-110, is currently undergoing a phase 1/2a trial in Australia and New Zealand for Alpha-1 antitrypsin deficiency (AATD), with an interim readout pencilled in for the second half of the year. KRRO-110 is an RNA editing oligonucleotide encapsulated in a lipid nanoparticle that is delivered to liver cells and designed to correct the AAT protein.
-
1 week ago |
fiercebiotech.com | James Waldron
California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical and clinical-stage life sciences companies. The Vivo Opportunity Fund is an evergreen public fund that runs in three-year investment cycles. The latest third cycle will continue the previous cycles’ focus on investing in “small- and mid-cap biotechnology and life sciences companies … to capture value from breakthroughs and clinical milestones,” according to a May 7 release.
-
1 week ago |
fiercebiotech.com | James Waldron
Neurocrine Biosciences has handed back two discovery-stage gene therapy programs to Voyager Therapeutics, although the companies’ wider central-nervous-system-focused collaboration remains on track. The biotechs have been working together in the CNS space since a $1.7 billion biobucks pact in 2019, with their relationship strengthened in 2023 to focus on Voyager’s gene therapy program for Parkinson’s disease and other GBA1-mediated diseases.
-
1 week ago |
fiercebiotech.com | James Waldron
C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF degrader program in order to focus on its IKZF1/3 degrader cemsidomide. The Massachusetts-based biotech has already completed a phase 1 trial of CFT1946, which is designed to treat BRAF V600 mutant solid tumors.
-
2 weeks ago |
fiercebiotech.com | James Waldron
Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at least for the time being. As the dust settles on the first significant week of quarterly earnings calls since the Trump administration made clear that tariffs on pharmaceutical imports are a live option, executives at some of the biggest drugmakers insisted they are staying focused on their existing plans.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 2K
- Tweets
- 10K
- DMs Open
- No
Interesting to hear GSK CEO Emma Walmsley say that Big Pharma should "run towards" conversations about vaccine efficacy as the new U.S. admin approaches. My initial writeup of the #JPM2025 session is here... https://t.co/ir4daAfdFx
For this week's @FierceBiotech podcast, I caught up with @novonordisk's Marcus Schindler to talk about the future of GLP-1s and the lessons he's learned as Chief Scientific Officer https://t.co/82yunwgPuE
My dispatch from Day 1 of Jefferies 2024 - where everyone is now making the comparison with JPM (including the bad weather)
Jefferies London Healthcare Conference, which until last year had been a relatively cozy affair, has seemingly become a victim of its own success. Is the meeting the next JPM? https://t.co/Z1FVDYQX4e
